Timo Minssen appointed as Professor of Biotechnology Law – University of Copenhagen

Global Genes Local Concerns > News > Timo Minssen appointed...

09 May 2016

Timo Minssen appointed as Professor of Biotechnology Law

The Faculty of Law congratulates Timo Minssen on his appointment as Professor of Biotechnology Law from 1 May 2016.

He is a highly recognized international authority with numerous publications covering the interface of Intellectual Property, Competition & Regulatory Law. His studies have a strong cross-disciplinary focus on emerging technologies in the pharma & life science sectors and cover a broad variety of legal issues during the lifecycle of biotechnological products and processes. He is also a regular contributor on Harvard Law School's "Bill of Health" blog and co-heads the Copenhagen Biotech & Pharma Forum (CBPF).

Professor Minssen holds a German law degree (Staatsexamen) from Georg-August-University in Göttingen, as well as biotech & IPR related LL.M., LL.Lic., and LL.D. degrees from Lund University and Uppsala University. In 2012 he published a comprehensive study on the US and European patentability of biopharmaceutical technology, which has been awarded the Swedish King Oscar stipendium. For 2016, he has been appointed Visiting Research Fellow at the University of Cambridge. He has also been a Visiting Research Fellow at the University of Oxford, Harvard Law School, the Chicago-Kent College of Law, and a Max Planck scholarship holder at the Max Planck Institute for Innovation & Competition. Before joining the University of Copenhagen in 2009, Professor Minssen was trained in the German Court system, at the European Patent Office and was engaged in interdisciplinary epigenetics research at the Pufendorf Institute for Advanced Studies in Lund.

Dean Jacob Graff Nielsen states: “The appointment of Timo Minssen as Professor in Biotechnology Law not only strengthens the Faculty's interdisciplinary education and research profile, but also meets an important societal need: To develop the legal framework ensuring optimal innovation, i.e. of biotechnological products and processes."